PATENT CLAIM ANALYSIS

Application Number: 16020641
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-11
Patent Classification: ["514", "176000"]

Abstract:
Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein  , R 1 , R 2 , R 3a , R 3b , R 4a , R 4b , R 5 , R 6 , and R 7  are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

Claim (Index 48):
A method of treating a CNS-related disorder selected from the group consisting of a sleep disorder and a mood disorder, comprising administering to the subject an effective amount of a compound of the formula

Metadata:
- Claim Count in Document: 35.0
- Percentile: 94.0
- Lexical Diversity: 1.75714
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15143312', '15297845', '14785175', '14785171', '14785192']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7701361659781141
- 35 USC 102 Novelty (BERT): 0.5368836193042978
- Combined Prediction Score: 0.7468109113107325
- Mean Citation Score: 321.727212
- Max Citation Score: 346.85098
- Similarity Product: 236.9542837722277

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test